J Frontier Co.,Ltd. agreed to acquire 67% stake in Wellvenus Co., Ltd from Masaki Nakano, Yoshifumi Hamaguchi and others for ¥1.5 billion.
February 28, 2024
Share
J Frontier Co.,Ltd. (TSE:2934) agreed to acquire 67% stake in Wellvenus Co., Ltd from Masaki Nakano, Yoshifumi Hamaguchi and others for ¥1.5 billion on February 29, 2024. Wellvenus Co., Ltd Reported Total revenue of ¥2.8 billion, Total assets worth ¥691 million, EBIT of ¥56.4 million, Total Common equity of ¥176 million and Net Loss of ¥43.9 million as on March 31, 2023. Transaction is expected to Complete on March 1, 2024.
J Frontier Co Ltd is a Japan-based company mainly engaged in the electronic commerce sale business for healthcare-related products and pharmaceuticals, the provision of online medication guidance, drug delivery platform SOKUYAKU, as well as the Internet advertising agency business for healthcare-related services. The Company operates through three business segments. The Healthcare Sales segment is engaged in the planning and development of health foods and cosmetics represented by the 328 selection series of fermented hydrogen and mail-order sales. The Medical Care Sales segment is engaged in the operation of dispensing pharmacies, mail-order business of ethical drugs, as well as planning, development and mail-order sales of drugs such as Why Pure series and Chinese herbs. The Health Care Marketing segment is mainly engaged in advertising agency business related to health care products, sales promotion support for health care products, as well as wholesale of in-house products.
J FRONTIER CO.,LTD. 
